HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The stock option awards have exercise prices of
The RSUs vest in eight successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the first calendar quarter that begins after the grant date, subject to the new employee’s continued service relationship with HTG through the applicable vesting dates. Each award has a 10-year term and is subject to the terms and conditions of HTG’s 2021 Inducement Plan and its standard form of agreement for inducement grants of restricted stock units.
The stock options and RSUs were granted as inducements material to the new employees entering into employment with HTG in accordance with Nasdaq Listing Rule 5635(c)(4).
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
Phone: (617) 430-7577
Source: HTG Molecular Diagnostics, Inc.